Hypothalamic and Pituitary Hormones Flashcards
What is a negative regulator of GH?
Somatostatin
What is a negative regulator of prolactin?
Dopamine
The effects of GH are mediated through
IGF-1
Physiological Actions of GH in childhood
Promotes linear growth
Growth of long bones, cartilage, muscle, organ systems
Physiological Actions of GH in adulthood
Increases protein synthesis and bone density
Promotes lipolysis, inhibits lipogenesis
Promotes gluconeogenesis and glucose release
Opposes insulin-induced glucose uptake in adipose tissue, reduces insulin sensitivity
Features of GH deficiency in children
short stature
Adiposity
hypoglycemia
Features of GH deficiency in adults
increased generalized adiposity Decreases skeletal muscle mass decreased bone density Cardiac muscle atrophy Atherogenic blood lipid profile Fatigue, weakness, depression, malaise
synthetic GHRH
Sermorelin
Sermorelin (synthetic GHRH) indication
used if defective GHRH release but normally functioning anterior pituitary somatotrophs
Recombinant human GH
Somatropin
Somatrem
Recombinant IGF-1
Mecasermin
Mecasermin (recombinant IGF-1) indication
Used in children where IGF-1 deficiency is due to mutations of GH receptor: Laron dwarfism or Ab against GH
Somatropin formulation
191-amino acid peptide, identical to native hGH
Somatrem
192-amino acid peptide consistign of 191aa of GH plus extra methionine residue at N-terminus (for stability, less allergic response)
Recombinant hGH (somatropin, somatrem) MOA
replaces GH
Recombinant hGH (somatropin, somatrem) Indications
Documented growth failure in pediatric pts with: GH deficiency Chronic renal failure Prader-Willi syndrome Turner syndrome
SGA w/ failure to catch up by 2
Idiopathic short stature, non GH-deficient (>2.25 S.D. below mean height)
GH deficiency in adults
Wasting in AIDS pts
Short bowel syndrome
Recombinant hGH (somatropin, somatrem) efficacy in children
Increases linear growth
Weight gain
Increases muscle mass, organ size, RBCs
Recombinant hGH (somatropin, somatrem) efficacy in adults
Increases bone mineral density Decreased central adiposity Increases muscle mass Improves lipid profile Improves cardiac function Improves sense of well being
Recombinant hGH (somatropin, somatrem) side effects
Leukemia Rapid growth of melanocytic lesions Hypothyroidism (GH counteracts TSH) Insulin resistance Arthralgia Increase in cytochrome p450 activity
Recombinant hGH (somatropin, somatrem) contraindications
Ped pts with closed epiphyses Intracranial lesion Active malignancy Proliferative diabetic retinopathy Cautin in diabetes
What is the effect of glucocorticoids on somatropin
Inhibit growth-promoting effect
What is the most common cause of growth hormone excess
Benign anterior pituitary tumor
Growth hormone excess in children
Gigantism
Occurs before the closure of epiphyses because excess IGF1 causes excessive longitudinal bone growth
Growth hormone excess in adults
Acromegaly
Occurs after epiphyses close, IGF-1 promotes growth of deep organs and cartilaginous tissue
Characteristics of acromegaly
thickening of bone (face, hands)
Large facial structure
Macroglossia
Hepatomegaly
Standard treatment for larger pituitary adenoma
Transsphenoidal surgery to remove the tumor
Medical options for smaller adenomas
Somatostatin analogues
GH receptor antagonist
Dopamine receptor agonist
Somatostatin analogues
Octreotide
Lanreotide (Europe)
GH receptor antagonist
Pegvisomant
Dopamine receptor agonist
Bromocriptine
Octreotide
Synthetic long-lasting peptide analogue of somatostatin
Octreotide MOA
Inhibits GH secretion
Octreotide indication
Control pituitary adenoma growth in acromegalic patients
Carcinoid crisis (flushing, diarrhea)
Secretory diarrhea from VIPoma
To control acute GI bleeding
Octreotide Side Effects
Nausea, vomiting, abdominal cramps, GI discomfort
Cardiac effects
Hypoglycemia
Gallstones
Octreotide Therapeutic Considerations
Decreases cyclosporin levels
Increases the availability of bromocriptine
GH Receptor Antagonist
Pegvisomant
Pegvisomant structure
Recombinat protein of 191 aa with mutliple polyethylene glycol (PEG) residues -prolongs half life
Pegvisomant MOA
Normally GH binds 2 receptors, dimerizes > signal transduction. Pegvisomant does not bind to the 2nd receptor, blocks signal transfuction = competitive antagonist of GH
Decreases serum IGF-1
Pegvisomant Indications
Acromegaly that is refractory to other treatment